BioCentury
ARTICLE | Preclinical News

Broad ErbB inhibition arrests KRAS mutant cancer

June 20, 2018 10:54 PM UTC

Multi-ErbB inhibitors may provide a treatment option for K-Ras (KRAS)-driven lung cancer where ErbB family member EGFR1-specific therapies have failed, according to two studies published in Science Translational Medicine on Wednesday.

The findings suggest a way to indirectly inhibit the downstream functions of KRAS while the field continues to develop strategies to selectively target the kinase, whose lack of druggable structural features has made the task difficult...